The use of laboratory tests in diagnosis and monitoring of systemic lupus erythematosus

Journal of Nephrology

Volumn 15, Issue SUPPL. 6, 2002, Pages

  Sinico, Renato Alberto ^a   Bollini, Bruna ^a   Sabadini, Ettore ^a   Di Toma, Luca ^a   Radice, Antonella ^a  

^a SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

Anti C1q antibodies; Anti dsDNA antibodies; Anti extractable nuclear antigens (ENA) antibodies; Anti nuclear antibodies (ANA); Anti nucleosome antibodies; Anti phospholipid antibodies; Systemic lupus erythematosus (SLE)

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; CELL NUCLEUS ANTIGEN; DOUBLE STRANDED DNA ANTIBODY; LUPUS ANTICOAGULANT; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOLIPID;

ANTIBODY DETECTION; BIOLOGICAL MONITORING; CRITHIDIA; CRITHIDIA LUCILIAE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEP 2 CELL; HUMAN; IMMUNOFLUORESCENCE; IMMUNOLOGICAL MONITORING; LABORATORY TEST; NEPHRITIS; PATIENT MONITORING; RADIATION DETECTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE SPECIFICITY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; IMMUNOLOGY; STANDARD;

CLINICAL LABORATORY TECHNIQUES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MONITORING, IMMUNOLOGIC;

EID: 0036878216     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Tan EM, Smolen JS, McDougal JS, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wiik A, Wilson M, Koziol JA. A critical evaluation of enzyme immunoassay kits for detection of antinuclcar antibodies of defined specificities. II. Potential for quantitation of antibody content. J Rheumatol 2002; 29: 68-74.
2. Emlen W, O'Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum 1997; 40: 1612-8.
3. Cavanaugh A, Tomar R, Reville J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific antoantibodies to nuclear antigens. Arch Pathol Lab Med 2000; 124: 71-81.
4. Hollingsworth PN, Pummer SC, Dawkins RL. Antinuclear antibodies. In Peter JB and Shoenfeld Y Eds. Autoantibodies. Amsterdam: Elsevier Science B.V. 1990; 74-89.
5. Pisetsky DS. Anti-DNA and antoantibodies. Curr Opin Rheumatol 2000; 12: 364-8.
6. Arbuckle MR, James JA, Kohlhase KF, Rnbertone MV, Dennis GJ, Harley JB. Development of anti-dsDNA autoantibodies prior to clinica diagnosis of systemic lupus erythematosus. Scand J Immunol 2001; 54: 211-9.
7. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33: 634-43.
8. Hylkema MN, Huygen H, Kramers C, Wal Th J, de Jong J, van Bruggen MC, Swaak AJ, Berden JH, Smeenk RJ. Clinical evaluation of a modified ELISA, using photobiotinylated DNA, for the detection of anti-DNA antibodies. J Immunol Methods 1994; 170: 93-102.
9. Hylkema MN, van Bruggen MC, ten Hove T, de Jong J, Swaak AJ, Berden JH, Smeenk RJ. Histone-containing immune complexes are to a large extent responsible for anti-dsDNA reactivity in the Farr assay of active SLE patients. J Autoimmun 2000; 14: 159-68.
10. Avina-Zubieta JA, Galindo-Rodriguez G, Kwan-Yeung L, Davis P, Russell AS. Clinical evaluation of various selected ELISA kits for the detection of anti-DNA antibodies. Lupus 1995; 4: 370-4.
11. Takeuchi Y, Ishikawa O, Miyachi Y. The comparative study of anti-double stranded DNA antibody levels measured by radio-immunoassay and enzyme-linked immunosorbent assay in systemic lupus erythematosus. J Dermatol 1997; 24: 297-300.
12. Smeenk R, Hylkema M. Detection of antibodies to DNA: a technical assessment. Mol Biol Rep 1992; 17: 71-9.
13. Wong KH, Lawton JW, Cheng SK, Lee SS, Lau CS. Measurement of anti-dsDNA: a comparative study of two ELISA and the Crithidia assay. Pathology 1998; 30: 57-61.
14. Wigand R, Gottschalk R, Falkenbach A, Matthias T, Kaltwasser JP, Hoelzer D. Detection of dsDNA antibodies in diagnosis of systemic lupus erythematosus - comparative studies of diagnostic effectiveness of 3 ELISA methods with different antigens and a Crithidia luciliae immunofluorescence test. Rheumatology 1997; 56: 53-62.
15. Clarke MC, Carr R, Burdash NM, Chen ZY, Ainsworth SK. A comparison of three anti-double stranded DNA antibody assays on sera from SLE and other diseases. Diagn Immunol 1986; 4: 288-93.
16. Chretien P, Dauvin M, Helin P, Ocwieja T, Absalon YB, Johanet C. Comparison of indirect immunofluorescence on Crithidia luciliae of Farr test, and immunoenzymatic methods for the screening of anti-native DNA autoantibodies. Ann Biol Clin 1994; 52: 645-50.
17. Smeenk RJ, Berden JH, Swaak AJ. dsDNA autoantibodies. In Peter JB and Shoenfeld Y Eds. Autoantibodies. Amsterdam: Elsevier Science B.V. 1996; 227-36.
18. Bootsma H, Spronk PE, ter Borg EJ, Hummel EJ, de Boer G, Limburg PC, Kallemberg CG. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation. Ann Rheum Dis 1997; 56: 661-6.
19. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2342-9.
20. Burlingame RW, Rubin RL. Subnucleosome structures as substrates in enzyme-linked immunosorbent assays. J Immunol Methods 1990; 134: 187-99.
21. Burlingame RW. The clinical utility of antihistone antibodies: autoantibodies reactive with chromatin in systemic lupus erythematosus and drug-induced lupus. Clin Lab Med 1997; 17: 367-78.
22. Loizou S, Samarkos M, Norsworthy PJ, Cazabon JK, Walport MJ, Davies KA. Significance of anticardiolipin and anti-beta(2)-glycoprotein I antibodies in lupus nephritis. Rheumatology 2000; 39: 962-8.
23. Galli M, Finazzi G, Norbis F, Marziali S, Marchioli R, Barbui T. The risk of thrombosis in patients with lupus anticoagulant is predicted by their specific coagulation profile. Thromb Haemost 1999; 81: 695-700.
24. Berden JH, Smeenk RJ. Nucleosome-specific autoantibodies. In Peter JB and Shoenfeld Y Eds. Autoantibodies. Amsterdam: Elsevier Science B.V. 1996; 574-81.
25. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994; 94: 184-92.
26. Amount Z, Piette JC, Bach JF, Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum 1999; 42: 833-43.
27. Rubin RL. Histone (H2A-H2B)-DNA autoantibodies. In Peter JB and Shoenfeld Y Eds. Autoantibodies. Amsterdam: Elsevier Science B.V. 1996; 364-72.
28. Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L, Bach JF, Piette JC. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases. Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 76-84.
29. Bruns A, Bläss S, Hausdorf G, Burmester GR, Hiepe F. Nucleosome are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 2307-15.
30. Agnello V, Koffler D, Eisenberg JW, Winchester RJ, Kundel HG. C1q precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: characterization of high and low molecular weight types. J Exp Med 1971; 134 (suppl): S228.
31. Uwatoko S, Aotsuka S, Okawa M, Egusa Y, Yokohari R, Aizawa C, Suzuki K. Characterization of C1q-binding IgG complexes in systemic lupus erythematosus. Clin Immunol Immunopathol 1984; 30: 104-16.
32. Mannik M, Wener MH. Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum 1997; 40: 1504-11.
33. Siegert CE, Daha MR, Tseng CM, Coremans IE, van Es LA, Breedveld FC. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993; 52: 851-6.
34. Coremans IE, Spronk PE, Bootsma H, Daha MR, van der Voort EA, Kater L, Breedveld FC, Kallenberg CG. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis 1995; 26: 595-601.
35. Siegert CE, Daha MR, Halma C, van der Voort EA, Breedveld FC. IgG and IgA autoantibodies to C1q in systemic and renal diseases. Clin Exp Rheumatol 1992; 10: 19-23.
36. Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, Panzeri P, Testoni C, Tincani A, Banfi G, Balestrieri G, Schifferli JA, Meroni PL, Ponticelli C. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001; 37: 490-8.
37. Gunnarsson I, Ronnelid J, Huang YH, Rogberg S, Nilsson B, Lundberg I, Klareskog L. Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. Br J Rheumatol 1997; 36: 32-7.
38. Galeazzi M, Morozzi G, Sebastiani GD, Bellisai F, Marcolongo R, Cervera R, De Ramòn Garrido E, Fernandez-Nebro A, Houssiau F, Jedryka-Goral A, Mathieu A, Papasteriades C, Piette JC, Scorza R, Smolen J, and the European Concerted Action on the Immunogenetics of SLE. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. Clin Exp Rheumatol 1998; 16: 541-6.
39. Bakkaloglu A, Topaloglu R, Saatçi U, Özdemir S, Özen A, Bassoy Y, Besbas N. Antineutrophil cytoplasmic antibodies in childhood systemic lupus erythematosus. Clin Rheumatol 1998; 17: 265-7.
40. Neugebauer KM, Merrill JT, Wener MH, Lahita RG, Roth MB. SR proteins are autoantigens in patients with systemic lupus erythematosus. Importance of phosphoepitopes. Arthritis Rheum 2000; 43: 1768-78.
41. Negi VS, Aggarwal A, Dayal R, Naik S, Misra R. Complement degradation product C3d in urine: marker of lupus nephritis. J Rheumatol 2000; 27: 380-3.
42. Boehme MW, Nawroth PP, Kling E, Lin J, Amiral J, Riedesel J, Raeth U, Scherbaum WA. Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 572-7.
43. Wong CK, Li EK, Ho CY, Lam CW. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology 2000; 39: 1078-81.
44. Noris M, Bernasconi S, Casiraghi F, Sozzani S, Gotti E, Remuzzi G, Mantovani A. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995; 73: 804-9.
45. Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, Takahashi Y, Sasaki T, Furuichi K, Segawa C, Hisada Y, Ohta S, Takasawa K, Kobayashi K, Matsushima K. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. J Rheumatol 1999; 26: 568-73.